A study, published recently in Blood, has shown that older/less fit newly diagnosed myeloma patients treated with either melphalan, prednisolone and thalidomide (MPT-T) or melphalan, prednisolone and lenalidomide (mPR-R) had similar overall response rates, progression-free survival and overall survival. In this Phase III trial involving 306 patients with a median age of 75.7 years, median progression-free survival was 21 months and 18.7 months for MPT-T and mPR-R respectively, overall survival was 52.6 months compared with 47.7 months and response rates were 63.6% and 59.9% respectively. However, mPR-R was associated with fewer and less severe side-effects than MPT-T, resulting in better quality of life for patients.

Read full article